A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma With DNA-Repair Defects
Phase of Trial: Phase II
Latest Information Update: 18 Feb 2019
At a glance
- Drugs Olaparib (Primary)
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- 23 Jan 2019 Status changed from not yet recruiting to recruiting.
- 14 Jun 2018 Planned initiation date changed from 25 May 2018 to 3 Aug 2018.
- 28 Dec 2017 New trial record